Chemotherapy effectively suppresses interleukin-20, receptor activator of nuclear factor kappa-B ligand, and osteoprotegerin levels in patients with lung adenocarcinoma and bone metastasis | Zendy

Mingyang Yu | Zendy; Yun Su | Zendy; Daping Cui | Zendy; Qiang Sun | Zendy; Bowu Luan | Zendy; Dewei Zhao | Zendy

Open Access

Chemotherapy effectively suppresses interleukin-20, receptor activator of nuclear factor kappa-B ligand, and osteoprotegerin levels in patients with lung adenocarcinoma and bone metastasis

Author(s) -

Mingyang Yu,

Yun Su,

Daping Cui,

Qiang Sun,

Bowu Luan,

Dewei Zhao

Publication year - 2016

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.179085

Subject(s) - osteoprotegerin , rankl , medicine , lung cancer , osteoclast , chemotherapy , adenocarcinoma , bone metastasis , cytokine , rank ligand , metastasis , receptor , oncology , endocrinology , activator (genetics) , cancer research , cancer

Bone metastasis (BM) is common in patients with lung cancer. Osteolysis is caused by increased osteoclast activity. Interleukin-20 (IL-20) and receptor activator of nuclear factor kappa-B ligand (RANKL) are crucial for osteoclast formation. Osteoprotegerin (OPG) inhibits a receptor activator of RANKL/RANK signaling. The aims of this study were to analyze the serum levels of IL-20, OPG, and RANKL in patients with and without BM and to observe the effect of chemotherapy on these cytokines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research